专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023092052A1 METHODS AND COMPOSITIONS FOR REDUCING CENTRALIZED PAIN 审中-公开
公开(公告)号：WO2023092052A1
公开(公告)日：2023-05-25
申请号：PCT/US2022/080104
申请日：2022-11-18
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： DIMARTINO, Stephen , DAKIN, Paula , GEBA, Gregory , GAO, Haitao
IPC分类号： C07K16/22 , A61P19/02 , A61P29/00 , A61K39/00
摘要： Methods and compositions for treating centralized pain are disclosed. Methods and compositions for reducing pain or improving physical function are disclosed. In certain aspects, the subject has centralized pain and osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.

2. 发明申请

WO2023079430A1 METHODS OF TREATING MITOCHONDRIAL MYOPATHIES USING ANTI-GDF15 ANTIBODIES 审中-公开
公开(公告)号：WO2023079430A1
公开(公告)日：2023-05-11
申请号：PCT/IB2022/060469
申请日：2022-10-31
申请人： PFIZER INC.
发明人： ALBUQUERQUE, Bina Maria , WU, Zhidan
IPC分类号： C07K16/22 , A61P19/00 , A61P21/00
摘要： The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.

3. 发明申请

WO2023069421A1 ANTI-ACTIVIN A ANTIBODIES, COMPOSITIONS AND USES THEREOF 审中-公开
公开(公告)号：WO2023069421A1
公开(公告)日：2023-04-27
申请号：PCT/US2022/047001
申请日：2022-10-18
申请人： BYOMASS INC. , ADIMAB, LLC
发明人： JACKSON, Vivienne Margaret , NIELSON, Nels P.
IPC分类号： C07K16/22 , A61P35/00 , A61P43/00
摘要： Provided herein are antibody agents that bind specifically to Activin A, as well as compositions comprising Activin A antibody agents, and methods of making and using the same.

4. 发明申请

WO2023039359A1 METHODS OF TREATING CANCER AND TUMOR-RELATED WEIGHT LOSS AND CACHEXIA 审中-公开
公开(公告)号：WO2023039359A1
公开(公告)日：2023-03-16
申请号：PCT/US2022/075906
申请日：2022-09-02
申请人： NGM BIOPHARMACEUTICALS, INC.
发明人： CHAN, Daniel , DEPAOLI, Alexander, Mark , LICHTMAN, Josh , TRAN-MUCHOWSKI, Bich Ngoc , XIAO, Yi Qun , ZHA, Jiping , LUO, Jian
IPC分类号： A61P35/00 , C07K16/22 , C07K16/28
摘要： The present disclosure relates generally to methods of treating (i) a tumor (e.g., a solid tumor, an advanced solid tumor, a cancer), (ii) tumor-related weight loss, or (iii) tumor-related cachexia in a human patient, the method comprising administering to the human patient an anti-GDNF family receptor alpha-like (GFRAL) antibody, wherein the antibody inhibits GFRAL binding to Ret proto-oncogene (RET). The present disclosure also relates generally to methods of treating pancreatic cancer (e.g., an advanced pancreatic cancer, a metastatic pancreatic cancer, a pancreatic adenocarcinoma, a metastatic pancreatic adenocarcinoma, an MSI-H pancreatic cancer, a pancreatic ductal adenocarcinoma, a metastatic pancreatic ductal adenocarcinoma) in a human patient, comprising administering to the human patient (i) an anti-GFRAL antibody, wherein the antibody inhibits GFRAL binding to RET; (ii) paclitaxel; and (iii) gemcitabine.

5. 发明申请

WO2023023465A1 ANTI-VEGFR1 ANTIBODIES AND THEIR USES 审中-公开
公开(公告)号：WO2023023465A1
公开(公告)日：2023-02-23
申请号：PCT/US2022/074891
申请日：2022-08-12
申请人： JANSSEN BIOTECH, INC.
发明人： BREYER, Matthew D. , GONZALEZ VILLALOBOS, Romer A. , LI, Jingjun , RUTKOSKI, Thomas J. , SWANSON, Ronald V. , ZHENG, Gang , ZHENG, Songmao , ZHENG, Xirong
IPC分类号： C07K16/28 , A61P13/12 , C07K16/22
摘要： Disclosed herein are antibodies or antigen binding fragments thereof that bind vascular endothelial growth factor receptor 1 (VEGFR1), polynucleotides, vectors, host cells and methods of treating chronic kidney disease using the same.

6. 发明申请

WO2023001228A1 一种抗ANGPTL3抗体或其抗原结合片段的药物组合物及其用途审中-公开
公开(公告)号：WO2023001228A1
公开(公告)日：2023-01-26
申请号：PCT/CN2022/106993
申请日：2022-07-21
申请人：江苏恒瑞医药股份有限公司 , 上海恒瑞医药有限公司
发明人：杨喜琴 , 葛凌霄 , 王宏伟
IPC分类号： C07K16/22 , A61K39/395
摘要：一种抗ANGPTL3抗体或其抗原结合片段的药物组合物及其用途。具体地，所述药物组合物包含抗ANGPTL3抗体或其抗原结合片段以及醋酸-醋酸钠缓冲液；所述药物组合物还可以包含糖和表面活性剂，具有良好的抗体稳定性。

7. 发明申请

WO2023280952A1 ANTI-ERYTHROPOIETIN ANTIBODY 审中-公开
公开(公告)号：WO2023280952A1
公开(公告)日：2023-01-12
申请号：PCT/EP2022/068805
申请日：2022-07-06
申请人： ANDREMACON S.R.L.
发明人： MARFIA, Giovanni , NAVONE, Stefania Elena , SCALVINI, Giuseppe , CAMPANELLA, Rolando , ALOTTA, Giovanni Andrea , BARILLA, Emanuela
IPC分类号： C07K16/22 , A61K31/00 , A61K39/395 , A61P35/00 , A61P37/00 , C07K16/28
摘要： The present invention concerns the field of monoclonal antibodies, and describes an isolated anti-EPO antibody which binds human Erythropoietin (EPO) preventing its binding to specific receptors and inhibiting their signaling pathway. The invention further describes a polynucleotide encoding the anti-EPO antibody, a vector comprising the polynucleotide and a host cell comprising the vector. Furthermore, a method is described, for producing the antibody. The compounds of the invention, alone or in combination, are effective in the treatment of proliferative disorders such as cancers, where they cause the induction of apoptosis and overcome drug-resistance in cancer cells, cancer stem cells and in tumor endothelial cells, of autoimmune and non-autoimmune based chronic inflammatory diseases, in the treatment of patients undergoing organ or tissue transplant, in the treatment of haemophilic arthropathy, neurodegenerative diseases and neurological diseases in which neuro inflammation plays a role in pathogenesis, for example: multiple sclerosis, Parkinson's disease, Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, autoimmune disease with neurologic involvement, Amyotrophic Lateral Sclerosis, Neuromuscular Diseases, ophthalmic pathologies such as neovascular age related (NVAMD), macular degeneration, retinal vein occlusion (RVO), metabolic syndromes, diabetes, and neuropathic pain disorders and the invention described compositions comprising them and medical uses of the composition. In a further aspect, the invention discloses the antibody, composition, or immunoconjugate for use as a medicament.

8. 发明申请

WO2022265912A1 ANTIBODIES TARGETING AN AMPHIREGULIN-DERIVED CELL SURFACE NEO-EPITOPE 审中-公开
公开(公告)号：WO2022265912A1
公开(公告)日：2022-12-22
申请号：PCT/US2022/032834
申请日：2022-06-09
申请人： GUNDERSEN LUTHERAN MEDICAL FOUNDATION, INC.
发明人： KENNY, Paraic , LOFGREN, Kristopher , SREEKUMAR, Sreeja
IPC分类号： C07K16/22 , A61K35/15 , A61K45/06
摘要： Antibodies and antibody-drug conjugates that selectively bind to a membrane-associated extracellular portion of a cleaved amphiregulin precursor protein; methods of using the antibodies and antibody-drug conjugates to detect and inhibit the growth of neoplastic cells; pharmaceutical compositions containing the antibodies and/or antibody-drug conjugates as the active ingredient(s); kits containing the antibodies and/or antibody-drug conjugates.

9. 发明申请

WO2022263880A1 EPO VARIANTS AND MODULATORS 审中-公开
公开(公告)号：WO2022263880A1
公开(公告)日：2022-12-22
申请号：PCT/IB2021/055266
申请日：2021-06-15
申请人： ANDREMACON S.R.L.
发明人： MARFIA, Giovanni , NAVONE, Stefania Elena , SCALVINI, Giuseppe , CAMPANELLA, Rolando , ALOTTA, Giovanni Andrea , BARILLA, Emanuela
IPC分类号： A61P35/00 , A61K38/18 , C07K14/505 , C07K16/22 , A61K38/00
摘要： The invention relates to negative functional modulators of at least one variant of the non- erythrogenic erythropoietin (V-EPO) and pharmaceutical compositions or kits containing them. Such functional negative modulators of V-EPO may be a mono- or multi-specific antibody anti-EV3, anti-EV4, anti-EV1-4, anti-EV1-5, anti-EV1-1, or EV2-1, or anti-Epo receptor (EpoR) anti-EPHB4, anti-CSF2RB, an antisense oligonucleotide, DNA decoy, RNA decoy, a ribozyme, an antagomiR, a shRNA, LNA or siRNA. Several uses of these functional modulators are described, which have been advantageously employed as a medicament and for the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing organ or tissue transplantation, The invention also describes variants of EPO for use in the diagnosis and in the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing an organ or tissue transplantation and as a diagnostic agent. According to another aspect, a monoclonal antibody to at least one of the variants of the erythropoietin is described. According to yet another aspect, the use of at least one alternative splicing variant of non-erythrogenic EPO and the measurement thereof at tissue and/or systemic level is described, as well as the study of the methylation status of the promoters of the genes involved in the EPO signalling pathway (by way of example EPO, EPOR, EPHB4, CSF2RB), as diagnostic, prognostic and predictive markers of an oncological pathology, a proliferative pathology, neurodegenerative or inflammatory pathology.

10. 发明申请

WO2022256723A2 TGF-BETA INHIBITORS AND THERAPEUTIC USE THEREOF 审中-公开
公开(公告)号：WO2022256723A2
公开(公告)日：2022-12-08
申请号：PCT/US2022/032278
申请日：2022-06-03
申请人： SCHOLAR ROCK, INC.
发明人： GAN, Lu , SCHURPF, Thomas , CORICOR, George , JACKSON, Justin , LEE-HOEFLICH, Si Tuen , BRUECKNER, Christopher , MARTIN, Constance , FAUCETTE, Ryan
IPC分类号： G01N33/574 , A61K39/39 , A61K39/395 , G01N33/569 , A61P35/00 , C07K16/22 , A61K2039/505 , A61K2039/545
摘要： The present disclosure provides TGFβ inhibitor therapy for treating immunosuppressive conditions, cancer, and fibrosis, either as a monotherapy or combination/adjunct therapy. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and fibrosis and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式